EVALUATION OF EFFICACY OF PROPHYLACTICALLY USED PREMEDICATION FOR THE MANAGEMENT OF NAUSEA, VOMITING AND HYPERSENSITIVITY REACTIONS TO CISPLATIN, TAXANES AND FAC (5-FLUOROURACIL, ADRIAMYCIN (DOXORUBICIN) AND CYCLOPHOSPHAMIDE) BASED CHEMOTHERAPY:
Main Article Content
Keywords
Pre Medication, nausea and vomiting, Hypersensitivity Reactions, Chemotherapy, Cisplatin, Taxanes, FAC
Abstract
To assess pre medication’s efficacy for managing nausea, vomiting and hypersensitivity reactions before chemotherapy. An observational prospective study was conducted at Nuclear Institute of Medicine and Radiotherapy Hospital Jamshoro, Sindh, Pakistan, from November 2020 to July 2022. The study included 180 patients, aged 18-60 years. A validated questionnaire was used to record data of patients. Most frequent reaction was Tachycardia 40% in Cisplatin, 46% in Paclitaxel and 50% in Docetaxel, Hypotension 30% in Cisplatin, 40% in Paclitaxel and 5-Flouro Uracil (5-FU) and 43% in Docetaxel, Phlebitis 44% in Paclitaxel, Flushing 57% in Docetaxel, Skin rash 57% in Paclitaxel and 63% in Docetaxel, Oral sore 40% in 5-FU, Diarrhea 40% in Cisplatin, 54% in Paclitaxel, 63% in Docetaxel while 54% in Cyclophosphamide and Doxorubicin and 40% in 5-FU. Nausea, vomiting and hypersensitivity reactions were controlled significantly by the use of premedication in Cisplatin and FAC based chemotherapy while in taxane-based chemotherapy these reactions were observed in moderate range.
References
2. Lorusso D, Bria, E, Costantini A, et al.. Patients’ perception of chemotherapy side effects: expectations, doctor-patient communication and impact on quality of life- An Italian survey. European Journal of Cancer Care. 2017; 26(2). doi.org/10.1111/ecc.12618
3. de Boer-Dennert M, de Wit R, Schmitz PI, et al., Patient perceptions of the side effects of chemotherapy: the influence of 5HT3 antagonists, British Journal of Cancer. 1997; 76(8): 1055–1061.
4. Roeland EJ, Ruddy KJ, BeBlanc TW, et al. What the HEC? Clinician adherence to evidence-based antiemetic prophylaxis for highly emetogenic chemotherapy. Journal of the National Comprehensive Cancer Network. 2020; 18(6): 676–681. https://doi.org/10.6004/jnccn.2019.7526
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis V1. 2021. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
6. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clinical Review in Allergy Immunology. 2003; 24: 253–262.
7. Robinson JB, Singh D, Bodurka-Bevers DC, et al. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecology Oncology. 2001: 82:550–558.
8. Boulanger J, Boursiquot JN, Cournoyer G et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Current Oncology. 2014; 21: 630–641. https://doi. org/10.3747/co.21.1966
9. Broyles AD, Banerji A, Barmettler S, et al. Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs. The Journal of Allergy and Clinical Immunology Practice. 2020; 8:S16-116. https://doi.org/10. 1016/j.jaip.2020.08.006
10. Bonamichi-Santos R, Castells M (2018) Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: reactions to taxanes and monoclonal antibodies. Clinical Review in Allergy Immunology. 54; 375–385. https:// doi.org/10.1007/s12016-016-8556-5
11. Pagani M, Bavbek S, Dursun AB, et al. Role of skin tests in the diagnosis of immediate hypersensitivity reactions to taxanes: results of a multicenter study. The Journal of Allergy and Clinical Immunology Practice. 2019 7:990–997.
12. Solimando DA, and Wilson JP. Doxorubicin-Induced Hypersensitivity Reactions. Drug Intelligence & Clinical Pharmacy. 1984;18(10):808-811. doi:10.1177/106002808401801007
13. Latreille J, Stewart D, Laberge F, et al. Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy. Supportive Care in Cancer, 1995;3:307-312.
14. Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. New England Journal of Medicine. 1995;332(1): 1-5.
15. Ritter HL, Gralla RJ, Hall SW, et al. Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. Cancer investigation.1998;16(2): 87-93.
16. Turan T, Bozok S, Erdoğan N, et al. Comparison of Antiemetic Effects of Ondansetron Granisetron and Tropisetron For Acute Emesis In Ovarian Cancer Patients Receiving Chemotherapy With Paclitaxel and Carboplatin. Gynecology Obstetrics & Reproductive Medicine. 2007;13(2): 107-111.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Shireen Bhurgri
Visiting Faculty, College Of Pharmacy, Liaquat University Of Medical and Health Sciences (LUMHS), Jamshoro, Sindh Pakistan
Shaneela Khowaja
Assistant Professor, Peoples Nursing School, Liaquat University Of Medical and Health Sciences (LUMHS), Jamshoro, Sindh Pakistan
Syed Mubashir Shah
Lecturer, College of Pharmacy, Liaquat University Of Medical and Health Sciences (LUMHS), Jamshoro, Sindh Pakistan
Narendar Kumar
Lecturer, faculty Of Pharmacy, University Of Sindh, Jamshoro, Sindh Pakistan
Bilal Mustafa
Assistant Professor, College Of Pharmacy, Liaquat University Of Medical and Health Sciences (LUMHS), Jamshoro Sindh Pakistan
Danish Patoli
Assistant Professor, College Of Pharmacy, Liaquat University Of Medical and Health Sciences (LUMHS), Jamshoro Sindh Pakistan
Rehana Arisar
Teaching Assistant, College of Pharmacy, Liaquat University of Medical and Health Sciences (LUMHS), Jamshoro Sindh Pakistan